CTCFL and laryngeal squamous cell carcinoma: Some reports on prostate cancer, glioblastoma, and laryngeal squamous cell carcinoma indicate that BORIS protein is absent or present at low levels in non-tumorigenic cells and tissues, but it is present at variable higher levels in all cancer cell lines and tumors, indicating that BORIS might be used as a cancer biomarker [48, 50, 58].